Literature DB >> 27840911

Gene silencing of USP1 by lentivirus effectively inhibits proliferation and invasion of human osteosarcoma cells.

Jinbo Liu1, Hongjun Zhu2, Ning Zhong3, Zifeng Jiang4, Lele Xu5, Youping Deng6, Zhenhuan Jiang7, Hongwei Wang8, Jinzhi Wang9.   

Abstract

Osteosarcoma is the most frequent malignant bone tumor, affecting the extremities of adolescents and young adults. Ubiquitin-specific protease 1 (USP1) plays a critical role in many cellular processes including proteasome degradation, chromatin remodeling and cell cycle regulation. In the present study, we discovered that USP1 was overexpressed in 26 out of 30 osteosarcoma tissues compared to cartilage tumor tissues and normal bone tissues. We then constructed a lentiviral vector mediating RNA interference (RNAi) targeting USP1 and demonstrated that it significantly suppressed the mRNA and protein expression of the USP1 gene in U2OS cells. Knockdown of USP1 inhibited the growth and colony-forming, as well as significantly reduced the invasiveness of U2OS cells. Western blot analysis indicated that suppression of USP1 downregulated the expression of many proteins including SIK2, MMP-2, GSK-3β, Bcl-2, Stat3, cyclin E1, Notch1, Wnt-1 and cyclin A1. Most of these proteins are associated with tumor genesis and development. RNAi of SIK2 significantly decreased SIK2 protein expression and inhibited the ability of forming colonies, as well as induced apoptosis and reduced the invasiveness of U2OS cells. Collectively, our results suggest that silencing USP1 inhibits cell proliferation and invasion in U2OS cells. Therefore, USP1 may provide a novel therapeutic target for the treatment of osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27840911     DOI: 10.3892/ijo.2016.3752

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  15 in total

1.  ML323, a USP1 inhibitor triggers cell cycle arrest, apoptosis and autophagy in esophageal squamous cell carcinoma cells.

Authors:  Yaxin Sun; Beibei Sha; Wenjing Huang; Miaomiao Li; Shan Zhao; Yuan Zhang; Jie Yan; Zheng Li; Jingwen Tang; Peiyan Duan; Jianxiang Shi; Pei Li; Tao Hu; Ping Chen
Journal:  Apoptosis       Date:  2022-06-02       Impact factor: 5.561

2.  Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12.

Authors:  Urszula L McClurg; Nay C T H Chit; Mahsa Azizyan; Joanne Edwards; Arash Nabbi; Karl T Riabowol; Sirintra Nakjang; Stuart R McCracken; Craig N Robson
Journal:  Oncogene       Date:  2018-05-14       Impact factor: 9.867

3.  Cellular redox sensor HSCARG negatively regulates the translesion synthesis pathway and exacerbates mammary tumorigenesis.

Authors:  Weicheng Zang; Chuanzhen Yang; Tingting Li; Liming Liao; Xiaofeng Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-03       Impact factor: 11.205

4.  MicroRNA-192-5p suppresses the initiation and progression of osteosarcoma by targeting USP1.

Authors:  Sheng Zhou; Min Xiong; Guo Dai; Ling Yu; Zhengpei Zhang; Jie Chen; Weichun Guo
Journal:  Oncol Lett       Date:  2018-03-06       Impact factor: 2.967

Review 5.  Salt-Inducible Kinase 2: An Oncogenic Signal Transmitter and Potential Target for Cancer Therapy.

Authors:  Fangyu Chen; Liuwei Chen; Qin Qin; Xinchen Sun
Journal:  Front Oncol       Date:  2019-01-22       Impact factor: 6.244

6.  Inhibition of Ubiquitin Specific Protease 1 Sensitizes Colorectal Cancer Cells to DNA-Damaging Chemotherapeutics.

Authors:  Xin Xu; Shaoyan Li; Ximao Cui; Kunkun Han; Jun Wang; Xiaodan Hou; Long Cui; Songbing He; Jiecheng Xiao; Yili Yang
Journal:  Front Oncol       Date:  2019-12-18       Impact factor: 6.244

Review 7.  STAT3 and its targeting inhibitors in osteosarcoma.

Authors:  Yun Liu; Shijie Liao; Samuel Bennett; Haijun Tang; Dezhi Song; David Wood; Xinli Zhan; Jiake Xu
Journal:  Cell Prolif       Date:  2020-12-31       Impact factor: 6.831

8.  The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival.

Authors:  Urszula L McClurg; Mahsa Azizyan; Craig N Robson; Daniel T Dransfield; Nivedita Namdev; Nay C T H Chit; Sirintra Nakjang
Journal:  Oncotarget       Date:  2018-05-18

9.  SIK2 attenuates proliferation and survival of breast cancer cells with simultaneous perturbation of MAPK and PI3K/Akt pathways.

Authors:  Neslihan Zohrap; Özge Saatci; Burcak Ozes; Ipek Coban; Hasan Murat Atay; Esra Battaloglu; Özgür Şahin; Kuyas Bugra
Journal:  Oncotarget       Date:  2018-04-24

10.  SIK2 represses AKT/GSK3β/β-catenin signaling and suppresses gastric cancer by inhibiting autophagic degradation of protein phosphatases.

Authors:  Xiao-Man Dai; Yan-Hui Zhang; Xiao-Han Lin; Xiao-Xing Huang; Yi Zhang; Chao-Rong Xue; Wan-Nan Chen; Jian-Xin Ye; Xin-Jian Lin; Xu Lin
Journal:  Mol Oncol       Date:  2020-11-20       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.